目的 探討硫酸特布他林霧化液聯(lián)合福多司坦片治療緩解期慢性阻塞性肺疾病的臨床療效。方法 選取2015年1月-2016年1月天津市南開醫(yī)院呼吸內(nèi)科收治的緩解期慢性阻塞性肺疾病患者102例，采用隨機數(shù)字表法將所有患者分為對照組和治療組，每組各51例。對照組口服福多司坦片，2片/次，3次/d。治療組在對照組基礎(chǔ)上霧化吸入硫酸特布他林霧化液，2 mg/次，3次/d。兩組患者均治療2周。觀察兩組的臨床療效，比較兩組的肺功能、血氣指標(biāo)和炎癥因子。結(jié)果 治療后，對照組和治療組的總有效率分別為76.5%、92.2%，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組呼氣高峰流量（PEFR）、用力呼氣中期流速占預(yù)測值的百分比（MMF%）、用力肺活量占預(yù)測值的百分比（FVC%）和第1秒用力呼氣量占預(yù)測值的百分比（FEV₁%）均明顯升高，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)上升程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組pO₂和pH值均明顯增高，pCO₂均明顯降低，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組血清白細(xì)胞介素-6（IL-6）和白細(xì)胞介素-8（IL-8）水平均明顯下降，α₁-抗胰蛋白酶（α₁-AT）水平均明顯升高，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 硫酸特布他林霧化液聯(lián)合福多司坦片治療緩解期慢性阻塞性肺疾病具有較好的治療效果，可改善肺功能，調(diào)節(jié)血氣指標(biāo)和炎癥因子，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical effect of Terbutaline Sulphate Solution for nebulization combined with Fudosteine Tablets in treatment of remission stage of chronic obstructive pulmonary disease. Methods Patients (102 cases) with remission stage of chronic obstructive pulmonary disease in Department of Respiratory Medicine of Tianjin Nankai Hospital from January 2015 to January 2016 were randomly divided into control and treatment groups according to the random number table method, and each group had 51 cases. Patients in the control group were po administered with Fudosteine Tablets, 2 tablets/time, three times daily. Patients in the treatment group were administered with aerosol inhalation of Terbutaline Sulphate Solution for nebulization on the basis of the control group, 2 mg/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and pulmonary function, blood gas indexes, and inflammatory factors in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 76.5% and 92.2%, respectively, and there was difference between two groups (P < 0.05). After treatment, PEFR, MMF%, FVC%, FEV₁%, and MVV% in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). The observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P < 0.05). After treatment, pO₂ and pH value in two groups were significantly increased, but the pCO₂ in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). The observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, thelevels of IL-6 and IL-8 in two groups were significantly decreased, but the levels of α₁-AT in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). The observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Terbutaline Sulphate Solution for nebulization combined with Fudosteine Tablets has clinical curative effect in treatment of remission stage of chronic obstructive pulmonary disease, can improve pulmonary function, and regulate blood gas indexes and inflammatory factors, which has a certain clinical application value.